Products & Portfolio (10)
1 discontinued product not shown
AZACITIDINE
azacitidine
Post-LOE
INTRAVENOUS, SUBCUTANEOUS · POWDER
Nucleic Acid Synthesis Inhibitors
refractory anemia with ringed sideroblasts (if accompanied by neutropeniathrombocytopeniarequiring transfusions)+5 more
2023
30
BORTEZOMIB
bortezomib
Post-LOE
INTRAVENOUS, SUBCUTANEOUS · INJECTABLE
Proteasome Inhibitors
myelomalymphoma
2022
30
DAPAGLIFLOZIN
dapagliflozin
Pre-Launch
SMORAL · TABLET
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.
type 2 diabetes mellitustype 1 diabetes mellitusheart failure+1 more
DECITABINE
decitabine
Post-LOE
INTRAVENOUS · INJECTABLE
Nucleic Acid Synthesis Inhibitors
untreatedde novosecondary MDS of all French-American-British subtypes (refractory anemia+9 more
2022
30
FULVESTRANT
fulvestrant
Post-LOE
INTRAMUSCULAR · SOLUTION
Estrogen Receptor Antagonists
2022
30
GEMCITABINE HYDROCHLORIDE
gemcitabine hydrochloride
Post-LOE
INJECTION · INJECTABLE
G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in the initiation of apoptotic cell death.
breast cancerlung cancer
2013
30
ICATIBANT ACETATE
icatibant
Post-LOE
SUBCUTANEOUS · INJECTABLE
B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
acute attacks of hereditary angioedema (HAE) in adults 18 years of ageolder
2020
30
MICAFUNGIN SODIUM
micafungin sodium
Post-LOE
INTRAVENOUS · INJECTABLE
[see Microbiology ()] .
Acute Disseminated CandidiasisAbscesses in adultolder
2021
30
PEMETREXED DISODIUM
pemetrexed disodium
Post-LOE
INTRAVENOUS · POWDER
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.
non-small cell lung cancerlung cancer
2022
30
VINORELBINE TARTRATE
vinorelbine
Post-LOE
INJECTION · INJECTABLE
2012
30
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 11 approved products
Top TAs: Oncology, Hematology, Metabolic Diseases
Portfolio Health
Pre-Launch1 (9%)
Post-LOE10 (91%)
11 total products
Therapeutic Area Focus
Marketed
Pipeline